Financhill
Back

Blueprint Medicines Quote, Financials, Valuation and Earnings

Is Elon Musk right about AI?

Learn all about it here.
Buy
70

BPMC
Blueprint Medicines

Last Price:
50.54
Seasonality Move:
6.01%

7 Day Trial

ALL ACCESS PASS

$ 7

Take advantage of the biggest IPO in history

Click here to see more

Blueprint Medicines Price Quote

$50.54
-0.10 (1.36%)
(Updated: September 2, 2023 at 6:00 AM ET)

Blueprint Medicines Key Stats

Buy
70
Blueprint Medicines (BPMC) is a Buy

Day range:
$49.95 - $50.86
52-week range:
$37.82 - $79.40
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.48
P/B ratio:
9.87%

Volume:
553.9K
Avg. volume:
725.3K
1-year change:
-31.41%
Market cap:
$3.1B
Revenue:
$204M
EPS:
$-9.22

How Much Does Blueprint Medicines Make?

Is Blueprint Medicines Growing As A Company?

  • What Is Blueprint Medicines's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.58%
  • What Is Blueprint Medicines's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Blueprint Medicines Stock Price Performance

What Is Blueprint Medicines 52-Week High & Low?

Blueprint Medicines Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Blueprint Medicines?

Is Blueprint Medicines Cash Flow Positive?

  • What Is BPMC Cash Flow From Operations?
    Cash flow from operations (TTM) is -$504.7M
  • What Is Blueprint Medicines’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $388.3M
  • What Is Blueprint Medicines’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $19.3M

Blueprint Medicines Return On Invested Capital

  • Is Management Doing A Good Job?
    BPMC return on invested capital is -86.99%
  • What Is Blueprint Medicines Return On Assets?
    ROA measures how assets are converting to revenues and is -43.79%
  • What Is BPMC Return On Equity?
    ROE is a measure of profitability and is -105.43%

Blueprint Medicines Earnings Date & Stock Price

Blueprint Medicines Competitors

  • Who Are Blueprint Medicines's Competitors?
    Below is a list of companies who compete with Blueprint Medicines or are related in some way:
    • Adamis Pharmaceuticals Corp (ADMP)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)
    • Recursion Pharmaceuticals Inc (RXRX)
    • Sarepta Therapeutics Inc (SRPT)

Blueprint Medicines Dividend Yield

Data Unavailable

Blueprint Medicines Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 11.94%
Revenue: 57.52% 26.24%

Analyst Recommendations

Buy Recommendations: 9
Hold Recommendations: 4
Sell Recommendations: 1
Price Target: 74.00
Upside from Last Price: 46.13%

Major Shareholders

  • How many BPMC shares are owned by institutional investors?
    97.1M BPMC shares are owned by institutional investors
  • How many BPMC shares are owned by insiders?
    1.3M BPMC shares are owned by insiders